Publication: 1045

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
      QxMD      Google Scholar   
Citation:
Cancer vol 119 (21) 3797-804
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
458  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-50701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
FLIPI score, epratuzumab, follicular lymphoma, monoclonal antibody, rituximab